<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625934</url>
  </required_header>
  <id_info>
    <org_study_id>VVX001-CS001</org_study_id>
    <nct_id>NCT03625934</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001</brief_title>
  <official_title>Study to Evaluate the Induction of HBV Virus Neutralizing Antibodies in Healthy Vaccine Naive Adults and Non-responders and in Patients Chronically Infected With HBV Using VVX001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viravaxx AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gouya Insights</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KKS MedUni Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Viravaxx AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Study will evaluate the effects of VVX001, a novel vaccine for hepatitis B, to&#xD;
&#xD;
        -  elicit a robust protective IgG immune response in vaccine naive subjects&#xD;
&#xD;
        -  in subjects who failed to demonstrate seroconversion after treatment with a licensed&#xD;
           hepatitis B vaccine and&#xD;
&#xD;
        -  in patients chronically infected with HBV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VVX001 is a recombinant fusion Protein composed of PreS from the large surface antigen of HBV&#xD;
      and Peptides derived from the grass pollen allergen Phl p 5. In a previous trial in allergic&#xD;
      but otherwise healthy subjects the product has been shown to elicit a potent IgG response to&#xD;
      the epitope of PreS1, which is responsible for binding to the cellular receptor NTCP. These&#xD;
      antibodies prevent infection with HBV in a cell culture model. The present study will&#xD;
      evaluate if such an immune response can also be achieved in four different patient&#xD;
      populations: 1) vaccine naive subjects; 2) subjects having failed to seroconvert upon&#xD;
      vaccination with a licensed HBV vaccine; 3) patients who are chronically infected with HBV,&#xD;
      but are classified as inactive carriers; 4) patients with active chronic HBV infection who&#xD;
      are HbEAg negative and chronically treated with nucleo(t)side (NUC) antiviral drugs. All&#xD;
      subjects will receive 5 s.c. injections of VVX001, the time course of antibody response to&#xD;
      PreS1 will be monitored in all of them. In cohort 4) NUC treatment will be withdrawn at&#xD;
      different timepoints during the study and the effect of treatment with VVX001 on hepatitis B&#xD;
      disease Parameters will be monitored. Subjects will be followed for 6 months after the of&#xD;
      treatment for Evaluation of a long-term effect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PreS specific IgG antibodies</measure>
    <time_frame>4 weeks after the last injection of study drug</time_frame>
    <description>Titer of PreS specific IgG antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PreS specific IgG, IgG1 and IgG4 antibodies</measure>
    <time_frame>4 weeks and 6 months after the last injection of study drug</time_frame>
    <description>Titers of PreS specific IgG, IgG1 and IgG4 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbSAg specific antibodies</measure>
    <time_frame>4 weeks and 6 months after the last injection of study drug</time_frame>
    <description>Titers of HbSAg specific antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of HBV infection</measure>
    <time_frame>4 weeks and 6 months after the last injection of study drug</time_frame>
    <description>Suppression of HBV infection in HepG2-NTCP cells using HBV strain D3 in cell culture with patient sera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell proliferation</measure>
    <time_frame>4 weeks and 6 months after the last injection of study drug</time_frame>
    <description>Proliferation of PreS specific CD4 and CD8 T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbSAg titers</measure>
    <time_frame>4 weeks and 6 months after the last injection of study drug</time_frame>
    <description>HbS Antigen titers will be measured in chronically infected patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA load</measure>
    <time_frame>4 weeks and 6 months after the last injection of study drug</time_frame>
    <description>HBV DNA load will be measured by PCR in chronically infected patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBVcrAg titers</measure>
    <time_frame>4 weeks and 6 months after the last injection of study drug</time_frame>
    <description>HBVcrAG titers will be measured in chronically infected patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Frequency, intensity and relatedness of adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>VVX001 (20 micrograms)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 5 injections of 20 micrograms each over a period of 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive 5 s.c. injections of matching placebo over a period of 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VVX001</intervention_name>
    <description>5 s.c. injections of 20 micrograms of VVX001 four weeks apart</description>
    <arm_group_label>VVX001 (20 micrograms)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 s.c. injections of matching Placebo four weeks apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cohort 1: hepatits B vaccine naive subjects Seronegative for anti-HBs and anti-HBc&#xD;
             antibodies and for HBs Antigen&#xD;
&#xD;
          -  Cohort 2: Subjects who failed to develop a protective immune response upon standard&#xD;
             vaccination with a licensed hepatitis B vaccine (&lt;10 IU/L anti HbS antibodies)&#xD;
             Seronegative for anti-HbS (&lt;10 IU/L) and anti-HBc antibodies and for HbSAg&#xD;
&#xD;
          -  Cohort 3: Parameters confirmed at screening during the past 12 months&#xD;
&#xD;
               1. HBeAg negative;&#xD;
&#xD;
               2. HbSAg positive at screening &lt;3000 IU/ml;&#xD;
&#xD;
               3. HBV viral load &lt;2000 IU/ml&#xD;
&#xD;
               4. ALT Levels ≤ULN at screening&#xD;
&#xD;
          -  Cohort 4a: Parameters confirmed at screening during the last 12 months&#xD;
&#xD;
               1. HBeAg negative;&#xD;
&#xD;
               2. HbSAg positive &lt;1000 IU/ml&#xD;
&#xD;
               3. HBV DNA not detectable for at least 2 years&#xD;
&#xD;
               4. History of nucleos(t)die Treatment for at least 3 years&#xD;
&#xD;
               5. Willingness to discontinue NUC treatment during study&#xD;
&#xD;
               6. ALT levels ≤ULN at screening&#xD;
&#xD;
          -  Cohort 4b: in addition to cohort 4a:&#xD;
&#xD;
               1. willingness to discontinue NUC treatment 6 weeks before entering the Study&#xD;
&#xD;
               2. ALT Levels ≤ULN 6 weeks before entering the study and&#xD;
&#xD;
                    -  5x ULN at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding females, adequate contraception required during the&#xD;
             treatment phase&#xD;
&#xD;
          -  History of grass pollen allergy&#xD;
&#xD;
          -  Co-infection with HCV, HDV, HIV&#xD;
&#xD;
          -  History of auto-immune hepatitis&#xD;
&#xD;
          -  Elevated Levels of Alpha-Fetoprotein (AFP) &gt;100 ng/ml&#xD;
&#xD;
          -  Documented history of decompensated liver disease (albumin &lt;3.5 g/dl and bilirubin&#xD;
             &gt;1.3 mg/dl)&#xD;
&#xD;
          -  Autoimmune disorders, transplant recipients, use of immunosuppressive or immune&#xD;
             modulating agents&#xD;
&#xD;
          -  Oral corticosteroids of 20 mg/week within the past 4 weeks prior to screening&#xD;
&#xD;
          -  History of treatment with PEG-IFN of IFN for at least 1 year prior to screening&#xD;
&#xD;
          -  History of evidence or conditions associated with chronic liver disease&#xD;
&#xD;
          -  Acute fever at time of enrolment&#xD;
&#xD;
          -  History of alcohol abuse&#xD;
&#xD;
          -  Planned administration of a vaccine not foreseen by study protocol in the period&#xD;
             starting 30 days before first product administration and during the entire study&#xD;
             period with exception of influenza vaccine&#xD;
&#xD;
          -  History of Cancer&#xD;
&#xD;
          -  Other severe co-morbid conditions and concurrent medication making the subject&#xD;
             unsuitable for participation&#xD;
&#xD;
          -  blood or plasma donation within 1 month of study enrolement and during the course of&#xD;
             the study&#xD;
&#xD;
          -  For all patients with chronic HBV infection:&#xD;
&#xD;
               1. Total bilirubin &gt;2x ULN confirmed by repeat testing within 2 weeks, unless&#xD;
                  historical documentation of Gilbert's syndrome&#xD;
&#xD;
               2. Documented or suspected hepatocelluar carcinoma&#xD;
&#xD;
               3. Presence of cholangitis, cholecystitis or bile duct obstruction&#xD;
&#xD;
               4. Liver cirrhosis assessed by fibroscan with elastography &lt;9kPa within the previous&#xD;
                  12 months and FIB-score &lt;3.2 at study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra Munda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helmut Brunar, PhD</last_name>
    <phone>+43 664 415 9511</phone>
    <email>h.brunar@viravaxx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ghazaleh Gouya, MD</last_name>
    <phone>+43 650 470 4206</phone>
    <email>gouya@gouya-insights.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Stauber, MD</last_name>
      <phone>+43 316 385 80268</phone>
      <email>rudolf.stauber@medunigraz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Wiedermann, MD</last_name>
      <phone>+43 1 40160 38290</phone>
      <email>ursula.wiedermann@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Petra Munda, MD</last_name>
      <phone>+43 1 40400 4741</phone>
      <email>petra.munda@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.viravaxx.com</url>
    <description>Sponsor website</description>
  </link>
  <reference>
    <citation>Cornelius C, Schöneweis K, Georgi F, Weber M, Niederberger V, Zieglmayer P, Niespodziana K, Trauner M, Hofer H, Urban S, Valenta R. Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. EBioMedicine. 2016 Sep;11:58-67. doi: 10.1016/j.ebiom.2016.07.023. Epub 2016 Aug 8.</citation>
    <PMID>27568223</PMID>
  </reference>
  <reference>
    <citation>Tulaeva I, Cornelius C, Zieglmayer P, Zieglmayer R, Schmutz R, Lemell P, Weber M, Focke-Tejkl M, Karaulov A, Henning R, Valenta R. Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32. EBioMedicine. 2020 Sep;59:102953. doi: 10.1016/j.ebiom.2020.102953. Epub 2020 Aug 24.</citation>
    <PMID>32855110</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

